Use of Alkaline Phosphatase (ALP) Activity and Disease Severity to Determine Secular Changes in Bone Disease as Applied to Paget’s Disease of the Bone

  • Luis Corral-GudinoEmail author
Reference work entry
Part of the Biomarkers in Disease: Methods, Discoveries and Applications book series (BDMDA)


A decrease in the prevalence of Paget’s disease of the bone during recent decades has been reported for different research groups. In addition to this change in prevalence, some authors have suggested a reduction in the severity of the disease. This secular change has been documented by a reduction in the extension of skeletal involvement and the finding of lower levels of ALP at diagnosis. The reasons for the change in prevalence and severity are poorly understood. Genetic factors which confer susceptibility for Paget’s disease, as SQSTM1 gene mutations, and their role on the severity of the disease have been suggested as possible explanation. Other factors, as the demographical or sociological changes in the susceptible populations, have been postulated as alternative hypothesis.


Alkaline phosphatase Paget’s disease Prevalence Secular trends SQSTM1 protein 

List of Abbreviations


Alkaline phosphatase


Colony stimulating factor 1


Nucleoporin 205-KD




Procollagen type I N-terminal propeptide


Promyelocytic leukemia


Ras and Rab interactor 3


Sequestosome 1 human protein


Transmembrane 7 superfamily, member 4


Tumor necrosis factor receptor superfamily


United Kingdom


  1. Al Nofal AA, Altayar O, BenKhadra K, Qasim Agha OQ, Asi N, Nabhan M, Prokop LJ, Tebben P, Murad MH. Bone turnover markers in Paget’s disease of the bone: a systematic review and meta-analysis. Osteoporos Int. 2015;26(7):1875–91.CrossRefPubMedGoogle Scholar
  2. Albagha OM, Visconti MR, Alonso N, Langston AL, Cundy T, Dargie R, Dunlop MG, Fraser WD, Hooper MJ, Isaia G, Nicholson GC, del Pino MJ, Gonzalez-Sarmiento R, Di SM, Tenesa A, Walsh JP, Ralston SH. Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget’s disease of bone. Nat Genet. 2010;42(6):520–4.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Albagha OM, Visconti MR, Alonso N, Wani S, Goodman K, Fraser WD, Gennari L, Merlotti D, Gianfrancesco F, Esposito T, Rendina D, Di SM, Isaia G, Brandi ML, Giusti F, del Pino-Montes J, Corral-Gudino L, Gonzalez-Sarmiento R, Ward L, Rea SL, Ratajczak T, Walsh JP, Ralston SH. Common susceptibility alleles and SQSTM1 mutations predict disease extent and severity in a multinational study of patients with Paget’s disease. J Bone Miner Res. 2013;28(11):2338–46.CrossRefPubMedGoogle Scholar
  4. Alvarez L, Guanabens N, Peris P, Monegal A, Bedini JL, Deulofeu R, Martinez de Osaba MJ, Munoz-Gomez J, Rivera-Fillat F, Ballesta AM. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget’s disease. J Bone Miner Res. 1995;10(3):458–65.CrossRefPubMedGoogle Scholar
  5. Alvarez L, Peris P, Pons F, Guanabens N, Herranz R, Monegal A, Bedini JL, Deulofeu R, Martinez de Osaba MJ, Munoz-Gomez J, Ballesta AM. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget’s disease activity. Arthritis Rheum. 1997;40(3):461–8.CrossRefPubMedGoogle Scholar
  6. Barker DJ, Gardner MJ. Distribution of Paget’s disease in England, Wales and Scotland and a possible relationship with vitamin D deficiency in childhood. Br J Prev Soc Med. 1974;28(4):226–32.PubMedPubMedCentralGoogle Scholar
  7. Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M, Torta M, Porpiglia F, Fontana D, Angeli A. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol. 2000;164(4):1248–53.CrossRefPubMedGoogle Scholar
  8. Bolland MJ, Cundy T. Paget’s disease of bone: clinical review and update. J Clin Pathol. 2013;66(11):924–7.CrossRefPubMedGoogle Scholar
  9. Collet C, Michou L, Audran M, Chasseigneaux S, Hilliquin P, Bardin T, Lemaire I, Cornelis F, Launay JM, Orcel P, Laplanche JL. Paget’s disease of bone in the French population: novel SQSTM1 mutations, functional analysis, and genotype-phenotype correlations. J Bone Miner Res. 2007;22(2):310–7.CrossRefPubMedGoogle Scholar
  10. Corral-Gudino L, Borao-Cengotita-Bengoa M, del Pino-Montes J, Ralston S, Corral-Gudino L, Garcia-Aparicio J, Sanchez-Gonzalez MD, Miron-Canelo JA, Blanco JF, Ralston SH, del Pino-Montes J. Epidemiology of Paget’s disease of bone: a systematic review and meta-analysis of secular changes. Bone. 2013a;55(2):347–52.CrossRefPubMedGoogle Scholar
  11. Corral-Gudino L, Garcia-Aparicio J, Sanchez-Gonzalez MD, Miron-Canelo JA, Blanco JF, Ralston SH, del Pino-Montes J. Secular changes in Paget’s disease: contrasting changes in the number of new referrals and in disease severity in two neighboring regions of Spain. Osteoporos Int. 2013b;24(2):443–50.CrossRefPubMedGoogle Scholar
  12. Coutris G, Cayla J, Rondier J, Talbot JN, Bonvarlet JP, Milhaud G. Analysis of disorders of the principal pathways of calcium metabolism in Paget’s disease. Effects of calcitonin administration. 26 cases. Rev Rhum Mal Osteoartic. 1975;42(12):759–67.PubMedGoogle Scholar
  13. Cremers S, Garnero P. Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. Drugs. 2006;66(16):2031–58.CrossRefPubMedGoogle Scholar
  14. Cundy T, McAnulty K, Wattie D, Gamble G, Rutland M, Ibbertson HK, Cundy HR, Gamble G, Wattie D, Rutland M, Cundy T. Evidence for secular change in Paget’s diseasePaget’s disease of bone in New Zealand: continued decline in disease severity. Bone. 1997;20(1):69–71.CrossRefPubMedGoogle Scholar
  15. Cundy HR, Gamble G, Wattie D, Rutland M, Cundy T. Paget’s disease of bone in New Zealand: continued decline in disease severity. Calcif Tissue Int. 2004;75(5):358–64.CrossRefPubMedGoogle Scholar
  16. Cundy T, Cundy T, Cundy T, McAnulty K, Wattie D, Gamble G, Rutland M, Ibbertson HK. Is the prevalence of Paget’s disease of bone decreasing? Is Paget’s disease of bone disappearing? Evidence for secular change in Paget’s disease. J Bone Miner Res. 2006;21(6):Suppl-13.Google Scholar
  17. Eekhoff ME, van der Klift M, Kroon HM, Cooper C, Hofman A, Pols HA, Papapoulos SE. Paget’s disease of bone in The Netherlands: a population-based radiological and biochemical survey – the Rotterdam Study. J Bone Miner Res. 2004;19(4):566–70.CrossRefPubMedGoogle Scholar
  18. Friedrichs WE, Reddy SV, Bruder JM, Cundy T, Cornish J, Singer FR, Roodman GD. Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget’s disease. J Bone Miner Res. 2002a;17(1):145–51.CrossRefPubMedGoogle Scholar
  19. Friedrichs WE, Reddy SV, Singer FR, Roodman GD. The pro and con of measles virus in Paget’s disease: pro. J Bone Miner Res. 2002b;17(12):2293.CrossRefGoogle Scholar
  20. Gennari L, Merlotti D, Martini G, Nuti R. Paget’s disease of bone in Italy. J Bone Miner Res. 2006;21:Suppl-21.Google Scholar
  21. Guanabens N, Rotes D, Holgado S, Gobbo M, Descalzo MA, Gorordo JM, Martinez-Ferrer MA, Salmoral A, Morales-Piga A. Implications of a new radiological approach for the assessment of Paget disease. Calcif Tissue Int. 2012;91(6):409–15.CrossRefPubMedGoogle Scholar
  22. Harris H. The human alkaline phosphatases: what we know and what we don’t know. Clin Chim Acta. 1990;186(2):133–50.CrossRefPubMedGoogle Scholar
  23. Helfrich MH, Hobson RP, Grabowski PS, Zurbriggen A, Cosby SL, Dickson GR, Fraser WD, Ooi CG, Selby PL, Crisp AJ, Wallace RG, Kahn S, Ralston SH. A negative search for a paramyxoviral etiology of Paget’s disease of bone: molecular, immunological, and ultrastructural studies in UK patients. J Bone Miner Res. 2000;15(12):2315–29.CrossRefPubMedGoogle Scholar
  24. Hocking LJ, Lucas GJ, Daroszewska A, Cundy T, Nicholson GC, Donath J, Walsh JP, Finlayson C, Cavey JR, Ciani B, Sheppard PW, Searle MS, Layfield R, Ralston SH. Novel UBA domain mutations of SQSTM1 in Paget’s disease of bone: genotype phenotype correlation, functional analysis, and structural consequences. J Bone Miner Res. 2004;19(7):1122–7.CrossRefPubMedGoogle Scholar
  25. Hood C, Johnson J, Kelly C. What is the prevalence of rheumatic disorders in general medical inpatients? Postgrad Med J. 2001;77(914):774–7.CrossRefPubMedPubMedCentralGoogle Scholar
  26. Howarths S. Cardiac output in osteitis deformans. Clin Sci (Lond). 1953;12(3):271–5.Google Scholar
  27. Khan SA, Brennan P, Newman J, Gray RE, McCloskey EV, Kanis JA. Paget’s disease of bone and unvaccinated dogs. Bone. 1996;19(1):47–50.CrossRefPubMedGoogle Scholar
  28. Langston AL, Campbell MK, Fraser WD, MacLennan GS, Selby PL, Ralston SH. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget’s disease of bone. J Bone Miner Res. 2010;25(1):20–31.CrossRefPubMedGoogle Scholar
  29. Lever JH. Paget’s disease of bone in Lancashire and arsenic pesticide in cotton mill wastewater: a speculative hypothesis. Bone. 2002;31(3):434–6.CrossRefPubMedGoogle Scholar
  30. Lopez-Abente G, Morales-Piga A, Elena-Ibanez A, Rey-Rey JS, Corres-Gonzalez J. Cattle, pets, and Paget’s disease of bone. Epidemiology. 1997;8(3):247–51.CrossRefPubMedGoogle Scholar
  31. Matthews BG, Afzal MA, Minor PD, Bava U, Callon KE, Pitto RP, Cundy T, Cornish J, Reid IR, Naot D. Failure to detect measles virus ribonucleic acid in bone cells from patients with Paget’s disease. J Clin Endocrinol Metab. 2008;93(4):1398–401.CrossRefPubMedGoogle Scholar
  32. Mee AP. Paramyxoviruses and Paget’s disease: the affirmative view. Bone. 1999;24(5:Suppl):Suppl-21S.Google Scholar
  33. Melton III LJ, Tiegs RD, Atkinson EJ, O'Fallon WM. Fracture risk among patients with Paget’s disease: a population-based cohort study. J Bone Miner Res. 2000;15(11):2123–8.CrossRefPubMedGoogle Scholar
  34. Merlotti D, Gennari L, Galli B, Martini G, Calabro A, De Paola V, Ceccarelli E, Nardi P, Avanzati A, Nuti R. Characteristics and familial aggregation of Paget’s disease of bone in Italy. J Bone Miner Res. 2005;20(8):1356–64.CrossRefPubMedGoogle Scholar
  35. Miron-Canelo JA, del Pino-Montes J, Vicente-Arroyo M, Saenz-Gonzalez MC. Epidemiological study of Paget’s disease of bone in a zone of the Province of Salamanca (Spain). The Paget’s disease of the bone study group of Salamanca. Eur J Epidemiol. 1997;13(7):801–5.CrossRefPubMedGoogle Scholar
  36. Morales-Piga AA, Bachiller-Corral FJ, Abraira V, Beltran J, Rapado A. Is clinical expressiveness of Paget’s disease of bone decreasing? Bone. 2002;30(2):399–403.CrossRefPubMedGoogle Scholar
  37. Ralston SH. Clinical practice. Paget’s disease of bone. N Engl J Med. 2013;368(7):644–50.CrossRefPubMedGoogle Scholar
  38. Ralston SH, Helfrich MH. Are paramyxoviruses involved in Paget’s disease? A negative view. Bone. 1999;24(5:Suppl):Suppl-18S.Google Scholar
  39. Ralston SH, Layfield R. Pathogenesis of Paget disease of bone. Calcif Tissue Int. 2012;91(2):97–113.CrossRefPubMedGoogle Scholar
  40. Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D. Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med. 2005;353(9):898–908.CrossRefPubMedGoogle Scholar
  41. Rendina D, Gennari L, De Filippo G, Merlotti D, de Campora E, Fazioli F, Scarano G, Nuti R, Strazzullo P, Mossetti G. Evidence for increased clinical severity of familial and sporadic Paget’s disease of bone in Campania, southern Italy. J Bone Miner Res. 2006;21(12):1828–35.CrossRefPubMedGoogle Scholar
  42. Renier JC, Bontoux-Carre E, Seret P, Villayleck S. How to evaluate the activity of Paget’s disease in clinical practice and which patients should be treated? Rev Rhum Mal Osteoartic. 1984;51(9):463–8.Google Scholar
  43. Renier JC, Cronier P, Audran M. A new anatomic index based on current knowledge for calculating the cumulative percentage of pagetic bone per subject and other parameters. Rev Rhum Engl Ed. 1995;62(5):355–8.PubMedGoogle Scholar
  44. Rima BK, Gassen U, Helfrich MH, Ralston SH. The pro and con of measles virus in Paget’s disease: con. J Bone Miner Res. 2002;17(12):2290–2.CrossRefPubMedGoogle Scholar
  45. Selby PL, Davies M, Mee AP. Canine distemper virus induces human osteoclastogenesis through NF-kappaB and sequestosome 1/P62 activation. J Bone Miner Res. 2006;21(11):1750–6.CrossRefPubMedGoogle Scholar
  46. Seton M, Choi HK, Hansen MF, Sebaldt RJ, Cooper C. Analysis of environmental factors in familial versus sporadic Paget’s disease of bone – the New England Registry for Paget’s disease of bone. J Bone Miner Res. 2003;18(8):1519–24.CrossRefPubMedGoogle Scholar
  47. Shankar S, Hosking DJ. Biochemical assessment of Paget’s disease of bone. J Bone Miner Res. 2006;21:Suppl-7.Google Scholar
  48. Solomon LR. Billiard-player’s fingers: an unusual case of Paget’s disease of bone. Br Med J. 1979;1(6168):931.CrossRefPubMedPubMedCentralGoogle Scholar
  49. Tan A, Ralston SH. Clinical presentation of Paget’s disease: evaluation of a contemporary cohort and systematic review. Calcif Tissue Int. 2014;95(5):385–92.CrossRefPubMedGoogle Scholar
  50. Tan A, Hudson J, Walker A, William F, MacLennan G, Ralston SH. Intensive bisphosphonate therapy increases the risk of fracture and requirement for orthopaedic surgery in Paget’s disease: the PRISM-EZ study. IBMS BoneKey. 2015;13(687):2.Google Scholar
  51. Tiegs RD, Lohse CM, Wollan PC, Melton LJ. Long-term trends in the incidence of Paget’s disease of bone. Bone. 2000;27(3):423–7.CrossRefPubMedGoogle Scholar
  52. Vellenga CJ, Pauwels EK, Bijvoet OL. Comparison between visual assessment and quantitative measurement of radioactivity on the bone scintigram in Paget’s disease of bone. Eur J Nucl Med. 1984;9(12):533–7.CrossRefPubMedGoogle Scholar
  53. Visconti MR, Langston AL, Alonso N, Goodman K, Selby PL, Fraser WD, Ralston SH. Mutations of SQSTM1 are associated with severity and clinical outcome in paget disease of bone. J Bone Miner Res. 2010;25(11):2368–73.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2017

Authors and Affiliations

  1. 1.Internal Medicine DepartmentHospital el BierzoPonferradaSpain

Personalised recommendations